187 related articles for article (PubMed ID: 11401781)
21. Advances in the use of angiogenesis inhibitors in cancer.
Pinedo HM
Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
[No Abstract] [Full Text] [Related]
22. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
23. Symposium on molecular pathogenesis of respiratory diseases and its clinical implication. 4. Molecular pathogenesis of lung cancer and its molecular targeted therapy.
Sone S; Shinohara T; Nishioka Y; Yano S
Intern Med; 2001 Feb; 40(2):167-70. PubMed ID: 11300157
[No Abstract] [Full Text] [Related]
24. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas.
Ding I; Sun JZ; Fenton B; Liu WM; Kimsely P; Okunieff P; Min W
Cancer Res; 2001 Jan; 61(2):526-31. PubMed ID: 11212245
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin.
Calvo A; Yokoyama Y; Smith LE; Ali I; Shih SC; Feldman AL; Libutti SK; Sundaram R; Green JE
Int J Cancer; 2002 Sep; 101(3):224-34. PubMed ID: 12209972
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Ellis LM; Takahashi Y; Liu W; Shaheen RM
Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
[TBL] [Abstract][Full Text] [Related]
28. [New molecular target of cancer therapy--angiogenesis regulator VEGF].
Toi M; Ueno T; Tominaga T
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2202-6. PubMed ID: 9422062
[TBL] [Abstract][Full Text] [Related]
29. Angiogenesis-research frontiers. A basic science conference of the New York Academy of Medicine.
Sepp-Lorenzino L; Pan BS
Expert Opin Investig Drugs; 2000 Apr; 9(4):929-35. PubMed ID: 11185425
[TBL] [Abstract][Full Text] [Related]
30. Anticancer drug targets: approaching angiogenesis.
Keshet E; Ben-Sasson SA
J Clin Invest; 1999 Dec; 104(11):1497-501. PubMed ID: 10587512
[No Abstract] [Full Text] [Related]
31. Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment.
Hayes AJ; Li LY; Lippman ME
BMJ; 1999 Mar; 318(7187):853-6. PubMed ID: 10092266
[No Abstract] [Full Text] [Related]
32. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
33. Endoglin (CD105): a target for anti-angiogenetic cancer therapy.
Fonsatti E; Altomonte M; Arslan P; Maio M
Curr Drug Targets; 2003 May; 4(4):291-6. PubMed ID: 12699349
[TBL] [Abstract][Full Text] [Related]
34. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic therapy in leukemia.
Thomas DA; Giles FJ; Cortes J; Albitar M; Kantarjian HM
Acta Haematol; 2001; 106(4):190-207. PubMed ID: 11815717
[TBL] [Abstract][Full Text] [Related]
36. [Anti-angiogenic reagents].
Shibuya M
Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1182-7. PubMed ID: 10771693
[No Abstract] [Full Text] [Related]
37. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
[TBL] [Abstract][Full Text] [Related]
38. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3.
Varner JA; Cheresh DA
Important Adv Oncol; 1996; ():69-87. PubMed ID: 8791129
[TBL] [Abstract][Full Text] [Related]
39. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
[TBL] [Abstract][Full Text] [Related]
40. [Research on the endothelium and new therapeutic strategies in tumors and cardiovascular diseases].
Dejana E
Recenti Prog Med; 1999 Feb; 90(2):64-8. PubMed ID: 10208094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
